Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies

Fig. 2

Proportion of patients achieving MCID for SF-36 PCS in A MTX-naïve patients, B MTX-IR patients, and C bDMARD-IR patients; proportion of patients achieving MCID for SF-36 MCS in D MTX-naïve, E MTX-IR, and F bDMARD-IR. Comparison with PBO or MTX: ***P < 0.001, **P < 0.01, *P < 0.05. All P values are exploratory (not adjusted for multiplicity) and were from logistic regression with treatment groups and stratification factors in the model. A nonresponder imputation was used for patients with missing data. MCID was defined as a ≥ 2.5-point increase from baseline. In the MTX-IR trial, patients on PBO were rerandomized to FIL 200 or 100 mg at week 24. The study in bDMARD-IR patients ended at week 24. ADA, adalimumab; bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; FIL, filgotinib; MCID, minimal clinically important difference; MCS, mental component score; MTX, methotrexate; PBO, placebo; PCS, physical component score; SF-36, Medical Outcomes Study 36-Item Short Form

Back to article page